JESUS PENA: Open Payments
NPI 1174596498 · ELIZABETH, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,373 in 85 payments from 11 companies in 2025. Trend: 2023 $1,394 · 2024 $1,285 · 2025 $1,373
Food & beverage: $1,373
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $353 |
| Teva Pharmaceuticals USA, Inc. | 15 | $240 |
| Alkermes, Inc. | 9 | $156 |
| Lundbeck LLC | 7 | $116 |
| Janssen Pharmaceuticals, Inc | 6 | $108 |
| Neurocrine BioSciences, Inc. | 6 | $108 |
| E.R. Squibb & Sons, L.L.C. | 5 | $91 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $80 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Vanda Pharmaceuticals Inc. | 2 | $35 |
Products named: VRAYLAR, UZEDY, ARISTADA, ABILIFY ASIMTUFII, INVEGA SUSTENNA, INGREZZA, COBENFY, CAPLYTA.
Industry payments across NJ — which companies pay providers there.
